{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:02:58Z","timestamp":1763748178399,"version":"3.37.3"},"reference-count":35,"publisher":"Bentham Science Publishers Ltd.","issue":"23","funder":[{"DOI":"10.13039\/501100001409","name":"DST","doi-asserted-by":"publisher","award":["DRDO: ERIP\/ER\/201903004\/M\/01\/1763"],"award-info":[{"award-number":["DRDO: ERIP\/ER\/201903004\/M\/01\/1763"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"SERB","doi-asserted-by":"publisher","award":["SERB: EMR\/2016\/000740"],"award-info":[{"award-number":["SERB: EMR\/2016\/000740"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,10,12]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The importance of inhibiting the kinases of the DDR pathway for radiosensitizing\ncancer cells is well established. Cancer cells exploit these kinases for their survival, which leads to\nthe development of resistance towards DNA damaging therapeutics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In this article, the focus is on targeting the key mediator of the DDR pathway, the ATM\nkinase. A new set of quinoline-3-carboxamides, as potential inhibitors of ATM, is reported.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Quinoline-3-carboxamide derivatives were synthesized and cytotoxicity assay was performed\nto analyze the effect of molecules on different cancer cell lines like HCT116, MDA-MB-468, and\nMDA-MB-231.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Three of the synthesized compounds showed promising cytotoxicity towards a selected set of\ncancer cell lines. Western Blot analysis was also performed by pre-treating the cells with quercetin, a\nknown ATM upregulator, by causing DNA double-strand breaks. SAR studies suggested the importance\nof the electron-donating nature of the R group for the molecule to be toxic. Finally, Western-Blot analysis\nconfirmed the down-regulation of ATM in the cells. Additionally, the PTEN negative cell line,\nMDA-MB-468, was more sensitive towards the compounds in comparison with the PTEN positive cell\nline, MDA-MB-231. Cytotoxicity studies against 293T cells showed that the compounds were at least\nthree times less toxic when compared with HCT116.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> In conclusion, these experiments will lay the groundwork for the evolution of potent and\nselective ATM inhibitors for the radio- and chemo-sensitization of cancer cells.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200731174216","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T16:56:38Z","timestamp":1596214598000},"page":"2070-2079","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Synthesis and Characterization of Quinoline-3-Carboxamide Derivatives as Inhibitors of the ATM Kinase"],"prefix":"10.2174","volume":"20","author":[{"given":"Srimadhavi","family":"Ravi","sequence":"first","affiliation":[{"name":"Department of Chemistry, Indian Institute of Technology Gandhinagar, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sugata","family":"Barui","sequence":"additional","affiliation":[{"name":"Department of Biological Engineering, Indian Institute of Technology Gandhinagar, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivapriya","family":"Kirubakaran","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Indian Institute of Technology Gandhinagar, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parul","family":"Duhan","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Indian Institute of Technology Gandhinagar, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushik","family":"Bhowmik","sequence":"additional","affiliation":[{"name":"Department of Biological Engineering, Indian Institute of Technology Gandhinagar, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.chembiol.2013.04.007","volume":"20","author":"Cheung-Ong K.","year":"2013","unstructured":"Cheung-Ong K.; Giaever G.; Nislow C.; DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol 2013,20(5),648-659","journal-title":"Chem Biol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1016\/j.febslet.2010.05.031","volume":"584","author":"Derheimer F.A.","year":"2010","unstructured":"Derheimer F.A.; Kastan M.B.; Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 2010,584(17),3675-3681","journal-title":"FEBS Lett"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"Pike K.G.","year":"2018","unstructured":"Pike K.G.; Barlaam B.; Cadogan E.; Campbell A.; Chen Y.; Colclough N.; Davies N.L.; De-Almeida C.; Degorce S.L.; Didelot M.; Dishington A.; Ducray R.; Durant S.T.; Hassall L.A.; Holmes J.; Hughes G.D.; Macfaul P.A.; Mulholland K.R.; McGuire T.M.; Ouvry G.; Pass M.; Robb G.; Stratton N.; Wang Z.; Wilson J.; Zhai B.; Zhao K.; Al-Huniti N.; The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (atm) kinase: the discovery of azd0156 (8-6-[3-(dimethylamino)propoxy]pyridin-3-yl-3-methyl-1-(tetrahydro-2 h-pyran-4-yl)-1,3-dihydro-2 h-imidazo[4. J Med Chem 2018,61,3823-3841","journal-title":"J Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/bph.12244","volume":"169","author":"Curtin N.J.","year":"2013","unstructured":"Curtin N.J.; Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol 2013,169(8),1745-1765","journal-title":"Br J Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nature03442","volume":"434","author":"Falck J.","year":"2005","unstructured":"Falck J.; Coates J.; Jackson S.P.; Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005,434(7033),605-611","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"Blackford A.N.","year":"2017","unstructured":"Blackford A.N.; Jackson S.P.; ATM, ATR, and DNA-PK: the trinity at the heart of the dna damage response. Mol Cell 2017,66(6),801-817","journal-title":"Mol Cell"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.3390\/biom5043204","volume":"5","author":"Velic D.","year":"2015","unstructured":"Velic D.; Couturier A.M.; Ferreira M.T.; Rodrigue A.; Poirier G.G.; Fleury F.; Masson J.Y.; DNA Damage signalling and repair inhibitors: the long-sought-after achilles\u2019 heel of cancer. Biomolecules 2015,5(4),3204-3259","journal-title":"Biomolecules"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc3007","volume":"11","author":"Begg A.C.","year":"2011","unstructured":"Begg A.C.; Stewart F.A.; Vens C.; Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011,11(4),239-253","journal-title":"Nat Rev Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","volume":"160","author":"Gavande N.S.","year":"2016","unstructured":"Gavande N.S.; VanderVere-Carozza P.S.; Hinshaw H.D.; Jalal S.I.; Sears C.R.; Pawelczak K.S.; Turchi J.J.; DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther 2016,160,65-83","journal-title":"Pharmacol Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"Weber A.M.","year":"2015","unstructured":"Weber A.M.; Ryan A.J.; ATM and ATR as therapeutic targets in cancer. Pharmacol Ther 2015,149,124-138","journal-title":"Pharmacol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.dnarep.2004.03.029","volume":"3","author":"Kurz E.U.","year":"2004","unstructured":"Kurz E.U.; Lees-Miller S.P.; DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004,3(8-9),889-900","journal-title":"DNA Repair (Amst)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dnarep.2015.12.009","volume":"39","author":"Guleria A.","year":"2016","unstructured":"Guleria A.; Chandna S.; ATM kinase: Much more than a DNA damage responsive protein. DNA Repair (Amst) 2016,39,1-20","journal-title":"DNA Repair (Amst)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1158\/1078-0432.CCR-07-5138","volume":"14","author":"Ashwell S.","year":"2008","unstructured":"Ashwell S.; Zabludoff S.; DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008,14(13),4032-4037","journal-title":"Clin Cancer Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1038\/onc.2013.275","volume":"33","author":"Cremona C.A.","year":"2014","unstructured":"Cremona C.A.; Behrens A.; ATM signalling and cancer. Oncogene 2014,33(26),3351-3360","journal-title":"Oncogene"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1021\/acs.jmedchem.5b01092","volume":"59","author":"Min J.","year":"2016","unstructured":"Min J.; Guo K.; Suryadevara P.K.; Zhu F.; Holbrook G.; Chen Y.; Feau C.; Young B.M.; Lemoff A.; Connelly M.C.; Kastan M.B.; Guy R.K.; Optimization of a novel series of ataxia-telangiectasia mutated kinase inhibitors as potential radiosensitizing agents. J Med Chem 2016,59(2),559-577","journal-title":"J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-14-3502","volume":"75","author":"McCabe N.","year":"2015","unstructured":"McCabe N.; Hanna C.; Walker S.M.; Gonda D.; Li J.; Wikstrom K.; Savage K.I.; Butterworth K.T.; Chen C.; Harkin D.P.; Prise K.M.; Kennedy R.D.; Mechanistic rationale to target pten-deficient tumor cells with inhibitors of the dna damage response kinase ATM. Cancer Res 2015,75(11),2159-2165","journal-title":"Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yexcr.2018.03.006","volume":"366","author":"Li K.","year":"2018","unstructured":"Li K.; Yan H.; Guo W.; Tang M.; Zhao X.; Tong A.; Peng Y.; Li Q.; Yuan Z.; ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin. Exp Cell Res 2018,366(1),24-33","journal-title":"Exp Cell Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1073\/pnas.1706392114","volume":"114","author":"Chen C-C.","year":"2017","unstructured":"Chen C-C.; Kass E.M.; Yen W-F.; Ludwig T.; Moynahan M.E.; Chaudhuri J.; Jasin M.; ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci USA 2017,114(29),7665-7670","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1158\/0008-5472.CAN-12-1702","volume":"73","author":"Liu Q.","year":"2013","unstructured":"Liu Q.; Xu C.; Kirubakaran S.; Zhang X.; Hur W.; Liu Y.; Kwiatkowski N.P.; Wang J.; Westover K.D.; Gao P.; Ercan D.; Niepel M.; Thoreen C.C.; Kang S.A.; Patricelli M.P.; Wang Y.; Tupper T.; Altabef A.; Kawamura H.; Held K.D.; Chou D.M.; Elledge S.J.; Janne P.A.; Wong K.K.; Sabatini D.M.; Gray N.S.; Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res 2013,73(8),2574-2586","journal-title":"Cancer Res"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat1719","volume":"4","author":"Durant S.T.","year":"2018","unstructured":"Durant S.T.; Zheng L.; Wang Y.; Chen K.; Zhang L.; Zhang T.; Yang Z.; Riches L.; Trinidad A.G.; Fok J.H.L.; Hunt T.; Pike K.G.; Wilson J.; Smith A.; Colclough N.; Reddy V.P.; Sykes A.; Janefeldt A.; Johnstr\u00f6m P.; Varn\u00e4s K.; Takano A.; Ling S.; Orme J.; Stott J.; Roberts C.; Barrett I.; Jones G.; Roudier M.; Pierce A.; Allen J.; Kahn J.; Sule A.; Karlin J.; Cronin A.; Chapman M.; Valerie K.; Illingworth R.; Pass M.;  The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models  Sci Adv, eaat17192018,4(6)","journal-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models  Sci Adv,"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jmedchem.6b00519","volume":"59","author":"Degorce S.L.","year":"2016","unstructured":"Degorce S.L.; Barlaam B.; Cadogan E.; Dishington A.; Ducray R.; Glossop S.C.; Hassall L.A.; Lach F.; Lau A.; McGuire T.M.; Nowak T.; Ouvry G.; Pike K.G.; Thomason A.G.; Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of ataxia telangiectasia mutated (atm) kinase. J Med Chem 2016,59(13),6281-6292","journal-title":"J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg212","volume":"51","author":"Andersson M.I.","year":"2003","unstructured":"Andersson M.I.; MacGowan A.P.; Development of the quinolones. J Antimicrob Chemother 2003,51(Suppl. 1),1-11","journal-title":"J Antimicrob Chemother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ejmech.2014.07.044","volume":"97","author":"Afzal O.","year":"2015","unstructured":"Afzal O.; Kumar S.; Haider M.R.; Ali M.R.; Kumar R.; Jaggi M.; Bawa S.; A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem 2015,97,871-910","journal-title":"Eur J Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.35","volume":"2","author":"Ahmed D.","year":"2013","unstructured":"Ahmed D.; Eide P.W.; Eilertsen I.A.; Danielsen S.A.; Ekn\u00e6s M.; Hektoen M.; Lind G.E.; Lothe R.A.; Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013,2","journal-title":"Oncogenesis"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2015.1053595","volume":"3","author":"McCabe N.","year":"2015","unstructured":"McCabe N.; Walker S.M.; Kennedy R.D.; When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers. Mol Cell Oncol 2015,3(1)","journal-title":"Mol Cell Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1128\/MCB.02047-07","volume":"28","author":"Hitomi M.","year":"2008","unstructured":"Hitomi M.; Yang K.; Stacey A.W.; Stacey D.W.; Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression. Mol Cell Biol 2008,28(17),5478-5493","journal-title":"Mol Cell Biol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.18632\/oncotarget.1687","volume":"5","author":"Janku F.","year":"2015","unstructured":"Janku F.; Kaseb A.O.; Tsimberidou A.M.; Wolff R.A.; Kurzrock R.; Identification of novel therapeutic targets in the PI3K\/AKT\/MTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget 2015,5(10),3012-3022","journal-title":"Oncotarget"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.dnarep.2003.10.014","volume":"3","author":"Ye R.","year":"2004","unstructured":"Ye R.; Goodarzi A.A.; Kurz E.U.; Saito S.; Higashimoto Y.; Lavin M.F.; Appella E.; Anderson C.W.; Lees-Miller S.P.; The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst) 2004,3(3),235-244","journal-title":"DNA Repair (Amst)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.bcp.2003.07.007","volume":"66","author":"O\u2019Prey J.","year":"2003","unstructured":"O\u2019Prey J.; Brown J.; Fleming J.; Harrison P.R.; Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. Biochem Pharmacol 2003,66(11),2075-2088","journal-title":"Biochem Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1021\/jm101520v","volume":"54","author":"Liu Q.","year":"2011","unstructured":"Liu Q.; Wang J.; Kang S.A.; Thoreen C.C.; Hur W.; Ahmed T.; Sabatini D.M.; Gray N.S.; Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem 2011,54(5),1473-1480","journal-title":"J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1135\/cccc20040453","volume":"69","author":"Z\u00e1letov\u00e1 J.","year":"2004","unstructured":"Z\u00e1letov\u00e1 J.; Dzurilla M.; Kutschy P.; Pazdera P.; Kov\u00e1\u010dik V.; Ald\u00f6lfi J.; Beke\u0161ov\u00e1 S.; Synthesis of 4,6-Disubstituted-2-(1H-Indol-3-Yl). Benzothiazoles Collect Czechoslov Chem Commun 2004,69,453-460","journal-title":"Benzothiazoles Collect Czechoslov Chem Commun"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.bmc.2016.04.001","volume":"24","author":"Ghinet A.","year":"2016","unstructured":"Ghinet A.; Moise I.M.; Rigo B.; Homerin G.; Farce A.; Dubois J.; B\u00eecu E.; Studies on phenothiazines: New microtubule-interacting compounds with phenothiazine A-ring as potent antineoplastic agents. Bioorg Med Chem 2016,24(10),2307-2317","journal-title":"Bioorg Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1039\/C4CY01227E","volume":"5","author":"John J.M.","year":"2015","unstructured":"John J.M.; Loorthuraja R.; Antoniuk E.; Bergens S.H.; Catalytic hydrogenation of functionalized amides under basic and neutral conditions. Catal Sci Technol 2015,5,1181-1186","journal-title":"Catal Sci Technol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1021\/jo0523417","volume":"71","author":"Carroll T.X.","year":"2006","unstructured":"Carroll T.X.; Thomas T.D.; Bergersen H.; B\u00f8rve K.J.; Saethre L.J.; Fluorine as a \u03c0 donor. Carbon 1s photoelectron spectroscopy and proton affinities of fluorobenzenes. J Org Chem 2006,71(5),1961-1968","journal-title":"J Org Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jmcb\/mju045","volume":"6","author":"Zannini L.","year":"2014","unstructured":"Zannini L.; Delia D.; Buscemi G.; CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol 2014,6(6),442-457","journal-title":"J Mol Cell Biol"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184452\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T20:48:01Z","timestamp":1613681281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184452\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":35,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,10,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200731174216","relation":{},"ISSN":["1568-0266"],"issn-type":[{"type":"print","value":"1568-0266"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}